Dossier assessment
Ixekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Ixekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Ixekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V
Press releases
Secukinumab and ixekizumab in psoriasis: considerable added benefit for certain patients
Additional information
Federal Joint Committee (G-BA)
2017-08-17 A G-BA decision was published.
Project details
- Project no.
- A17-07
- Commission
- Commission awarded on 27.02.2017 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Ixekizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ixekizumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ixekizumab (spondylitis and spondyloarthritis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ixekizumab (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ixekizumab (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed